GLENMARK

Glenmark Pharmaceuticals Share PriceGlenmark Pharmaceuticals

₹609.6
11.85 (1.98%)
  • Advice
  • Hold
As on 01 June, 2023 | 18:32 BSE: 532296 NSE: GLENMARK

Glenmark Pharmaceuticals Performance

Day Range

  • Low
  • High
609.6

52 Week Range

  • Low
  • High
609.6
  • Open Price
  • Previous Close
  • Volume

Start SIP in Glenmark Pharmaceuticals

Start SIP

Glenmark Pharmaceuticals Share Price

  • Over 1 Month 8.19%
  • Over 3 Month 42.06%
  • Over 6 Month 41.54%
  • Over 1 Year 56.75%

Glenmark Pharmaceuticals Key Statistics

P/E Ratio 54.5
PEG Ratio -0.8
Market Cap Cr 17,201
Price to Book Ratio 1.7
EPS 56.1
Dividend 0.4
Relative Strength Index 66.13
Money Flow Index 47.5
MACD Signal 24.62
Average True Range 15.38

Glenmark Pharmaceuticals Investment Rating

  • Master Rating:
  • Glenmark Pharms. (Nse) has an operating revenue of Rs. 12,990.11 Cr. on a trailing 12-month basis. An annual revenue growth of 7% is good, Pre-tax margin of 7% is okay, ROE of 3% is fair but needs improvement. The company has a reasonable debt to equity of 41%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 13% and 36% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 38 which is a POOR score indicating inconsistency in earnings, a RS Rating of 86 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 103 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Glenmark Pharmaceuticals Financials
IndicatorMar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 1,8752,1612,1531,8721,721
Operating Expenses Qtr Cr 1,7211,7231,8261,4781,624
Operating Profit Qtr Cr 218439382434162
Depreciation Qtr Cr 4746464542
Interest Qtr Cr 5956524074
Tax Qtr Cr -17615917720319
Net Profit Qtr Cr -137431423493206

Glenmark Pharmaceuticals Technicals

EMA & SMA

Current Price
₹609.6
11.85 (1.98%)
  • Bullish Moving Average
  • ___
  • 16
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • ₹588.43
  • 50 Day
  • ₹543.69
  • 100 Day
  • ₹499.98
  • 200 Day
  • ₹467.18
  • 20 Day
  • ₹595.74
  • 50 Day
  • ₹531.3
  • 100 Day
  • ₹474.57
  • 200 Day
  • ₹439.56

Glenmark Pharmaceuticals Resistance and Support

PIVOT
₹597.1
Resistance
First Resistance ₹602.46
Second Resistance ₹607.15
Third Resistance ₹612.5
RSI 66.13
MFI 47.5
MACD Single Line 24.62
MACD 19.95
Support
First Resistance ₹592.4
Second Resistance ₹587.05
Third Resistance ₹582.35

Glenmark Pharmaceuticals Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 1,075,939 47,685,616 44.32
Week 909,679 46,184,383 50.77
1 Month 1,906,964 83,906,406 44
6 Month 1,304,840 48,696,628 37.32

Glenmark Pharmaceuticals Result Highlights

Glenmark Pharmaceuticals Synopsis

NSE-Medical-Generic Drugs

Glenmark Pharma is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 8220.66 Cr. and Equity Capital is Rs. 28.22 Cr. for the Year ended 31/03/2023. Glenmark Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 18/11/1977 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24299MH1977PLC019982 and registration number is 019982.
Market Cap 17,201
Sales 8,221
Shares in Float 14.95
No of funds 280
Yield 0.42
Book Value 0.94
U/D Vol ratio 2
LTDebt / Equity 15
Alpha 0.13
Beta 0.89

Glenmark Pharmaceuticals

Owner NameMar-23Dec-22Sep-22Jun-22
Promoters 46.65%46.65%46.65%46.65%
Mutual Funds 5.43%5.64%6.26%5.81%
Insurance Companies 4.41%4.48%4.16%
Foreign Portfolio Investors 22.47%23.19%23.14%24.23%
Financial Institutions/ Banks 0.2%0.2%0.22%0.2%
Individual Investors 16.9%16.72%16.47%16.32%
Others 3.94%3.12%3.1%6.79%

Glenmark Pharmaceuticals Management

Name Designation
Mr. Glenn Saldanha Chairman & Managing Director
Mrs. Cherylann Pinto Executive Director - Corporate Affairs
Mr. V S Mani Executive Director & Global CFO
Mr. Rajesh V Desai Non Executive Director
Dr. Brian W Tempest Non Executive Director
Mr. Dipankar Bhattacharjee Non Executive Director
Mr. Bernard Munos Non Executive Director
Mr. Sridhar Gorthi Non Executive Director
Mrs. B E Saldanha Non Executive Director
Mr. D R Mehta Non Executive Director
Ms. Saira Ramasastry Non Executive Director

Glenmark Pharmaceuticals Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Glenmark Pharmaceuticals Corporate Action

Date Purpose Remarks
2023-05-19 Audited Results & Final Dividend
2023-02-10 Quarterly Results
2022-11-11 Quarterly Results
2022-08-10 Quarterly Results
2022-05-27 Audited Results & Final Dividend

Glenmark Pharmaceuticals MF Shareholding

Name Amount(cr)
HDFC Mid-Cap Opportunities Fund Growth 36912
Kotak Equity Arbitrage Fund Growth 20587
Aditya Birla Sun Life Flexi Cap Fund Growth 15935
Kotak Balanced Advantage Fund Regular Growth 14422
ICICI Prudential Equity Arbitrage Fund Regular Growth 10189

Glenmark Pharmaceuticals FAQs

What is Share Price of Glenmark Pharmaceuticals ?

Glenmark Pharmaceuticals share price is ₹609 As on 01 June, 2023 | 18:18

What is the Market Cap of Glenmark Pharmaceuticals ?

The Market Cap of Glenmark Pharmaceuticals is ₹17201 Cr As on 01 June, 2023 | 18:18

What is the P/E ratio of Glenmark Pharmaceuticals ?

The P/E ratio of Glenmark Pharmaceuticals is 54.5 As on 01 June, 2023 | 18:18

What is the PB ratio of Glenmark Pharmaceuticals ?

The PB ratio of Glenmark Pharmaceuticals is 1.7 As on 01 June, 2023 | 18:18

Q2FY23

Start Investing Now!

Open Free Demat Account in 5 mins

Enter Valid Mobile Number